Incidence of CLS and HUS in the Combined Safety Database of Hairy Cell Leukemia Patients Treated with LUMOXITI (N=129)1

In the combined safety database (N=129), 23% of patients experienced Grade 2 CLS.1

CLS and HUS management

  • CLS and HUS may be life-threatening or fatal if treatment is delayed.

CLS and HUS may occur during any cycle of treatment with LUMOXITI1